ALLO-605
ALLO-605-201
Phase 2 gene_therapy terminated
Quick answer
ALLO-605 for Relapsed/Refractory Multiple Myeloma is a Phase 2 program (gene_therapy) at Allogene Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Allogene Therapeutics
- Indication
- Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- terminated